HCW Biologics Stock (NASDAQ:HCWB)


RevenueOwnershipFinancialsChart

Previous Close

$4.26

52W Range

$3.55 - $100.80

50D Avg

$5.68

200D Avg

$12.89

Market Cap

$10.28M

Avg Vol (3M)

$786.59K

Beta

0.65

Div Yield

-

HCWB Company Profile


HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

36

IPO Date

Jul 20, 2021

Website

HCWB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceMar 25
Operating Segments$5.07K

Fiscal year ends in Dec 24 | Currency in USD

HCWB Financial Summary


Dec 24Dec 23Dec 22
Revenue$2.57M$2.84M$6.72M
Operating Income$-29.48M$-25.72M$-15.08M
Net Income$-30.02M$-24.99M$-14.72M
EBITDA$-29.48M$-23.58M$-14.18M
Basic EPS$-0.77$-0.70$-0.41
Diluted EPS$-0.77$-0.70$-0.41

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
CSBRChampions Oncology, Inc.
MOLNMolecular Partners AG
RNAZTransCode Therapeutics, Inc.
ABVCABVC BioPharma, Inc.
MNOVMediciNova, Inc.
EVAXEvaxion Biotech A/S
CLYMClimb Bio, Inc.
KTTAPasithea Therapeutics Corp.
RNXTRenovoRx, Inc.